Research programme: antibody therapeutics - Biotecnol

Drug Profile

Research programme: antibody therapeutics - Biotecnol

Alternative Names: CAB051; IR051; IR052; Tb 434; Tb 535

Latest Information Update: 29 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotecnol SA
  • Developer Biotecnol Inc.
  • Class Antibodies
  • Mechanism of Action CD3 antigen inhibitors; ERBB 2 receptor antagonists; Signal transducing adaptor protein inhibitors; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Research Breast cancer; Gastric cancer; Malignant melanoma; Mesothelioma

Most Recent Events

  • 07 Jan 2015 Interim adverse events and pharmacodynamics data from a preclinical study in Solid tumours released by Biotecnol
  • 05 Dec 2014 Research programme: multispecific antibodies - Biotecnol is available for licensing as of 05 December 2014 (http://www.biotecnol.com)
  • 04 Apr 2014 Biotecnol and Life and Health Sciences Research Institute (ICVS) enter research and collaboration agreement for preclinical research activities
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top